MedTrace Logo

Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric Cancer

NCT02525237 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2015-08-17

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of Apatinib combined with S-1 as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma.

Conditions

Interventions

DRUG

Apatinib

Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity

DRUG

S-1

S-1 (40 mg/m2 qd days 1-14 q3w p.o.) until disease progression or intolerable toxicity

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    collaborator INDUSTRY

  • Qingdao Municipal Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2016-08-31
Completion
2017-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02525237 on ClinicalTrials.gov